Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Schizoaffective Disorder: full-pipeline trial registry
31 of 105 indexed Schizoaffective Disorder trials are currently recruiting.
Corpus placement: #125 of 28,707 conditions by registered trial count.
105 US clinical trials · 31 currently recruiting · #125 of 28,707 conditions by registered trial count
Schizoaffective Disorder: 105 US clinical trials tracked, 31 recruiting.
Schizoaffective Disorder is the subject of 105 registered US clinical trials on ClinicalTrials.gov, 31 of them currently open to new participants. 20 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is University of Maryland, Baltimore, running 8 of these trials.
Enrollment posture brief
Registry condition schizoaffective-disorder
OPEN 31 | RECR 30% | LATE 20 | EARLY 21 | RANK #125 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Emphysema (30% recruiting · 27 trials)
Schizoaffective Disorder lists 31 open slots (30% of 105 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Schizoaffective Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Schizoaffective Disorder is recruiting below its size-band peers.
31 of 105 indexed trials (29.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Schizoaffective Disorder trials is spread across many organizations.
University of Maryland, Baltimore accounts for 8 of 105 trials (7.6%). 56 distinct sponsors appear on at least one study for this condition label.
-
Most Schizoaffective Disorder trials plan to enrol fewer than 100 people.
Median target enrolment is 67 among the 104 trials that report a genuine target (sentinel values excluded). 66 of those (63.5%) plan for fewer than 100 participants.
-
Schizoaffective Disorder research is mostly interventional.
99 interventional and 6 observational studies make up this index (94.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
105 total, page 2 of 3
Virtual Reality Job Interview Training in Severe Mental Illness
University of Michigan
NCT03049813
Work Activity Augmented by Cognitive Rehabilitation for Schizophrenia
VA Office of Research and Development
NCT00430560
A New Paradigm for Illness Monitoring and Relapse Prevention in Schizophrenia
Dartmouth-Hitchcock Medical Center
NCT01952041
Personalized and Scalable Cognitive Remediation Approaches
New York State Psychiatric Institute
NCT01945333
Cognitive-Behavioral Therapy in Veterans With Schizophrenia
VA Office of Research and Development
NCT00688259
Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI
Dartmouth-Hitchcock Medical Center
NCT02334280
Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder
H. Lundbeck A/S
NCT02901587
A Study of Strategies to Improve Schizophrenia Treatment
US Department of Veterans Affairs
NCT00156637
D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
Yale University
NCT00237809
Nicotinic Receptors and Schizophrenia
University of Colorado, Denver
NCT01400477
Mobile Self-Tracking of Mental Health
VA Office of Research and Development
NCT05023252
Luteolin for the Treatment of People With Schizophrenia
University of Maryland, Baltimore
NCT05204407
Oxytocin and CBSST for People With Schizophrenia
University of Maryland, Baltimore
NCT01752712
Cognitive - Behavioral Therapy
US Department of Veterans Affairs
NCT00018629
Cognitive Training for Patients With Schizophrenia
University of California, San Diego
NCT01521026
Improving Accessibility and Personalization of CR for Schizophrenia
New York State Psychiatric Institute
NCT03576976
Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant
Braeburn Pharmaceuticals
NCT02658357
Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia
Sheppard Pratt Health System
NCT01242371
Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence
Duke University
NCT00215579
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
University of California, San Diego
NCT04857983
The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia
Indiana University
NCT01339858
High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder
Manhattan Psychiatric Center
NCT00297947
In-person vs. Remote Wellness Support
The University of Texas Health Science Center at San Antonio
NCT04526067
Development of a Mobile System for Self-management of Schizophrenia (SOS)
Dartmouth-Hitchcock Medical Center
NCT01969500
Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder
University of Massachusetts, Worcester
NCT03526354
Omega-3 Dietary Supplements in Schizophrenia
Delbert Robinson
NCT01786239
Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness
University of Washington
NCT03062267
Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode
University of California, Los Angeles
NCT02267070
A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients
Luye Pharma Group
NCT03751488
Levetiracetam in Early Psychosis
NYU Langone Health
NCT03129360
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
Alkermes
NCT02636842
Using Transcranial Magnetic Stimulation (TMS) to Understand 'Negative' Symptoms of Schizophrenia
Beth Israel Deaconess Medical Center
NCT03648268
D-serine Augmentation of Neuroplasticity
New York State Psychiatric Institute
NCT03711500
Texting for Relapse Prevention
Center for Innovative Public Health Research
NCT02819349
Confirmatory Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies (AGA IG)
University of Maryland, Baltimore
NCT03183609
A Comparison of Two Cognitive Batteries in People With Schizophrenia
North Suffolk Mental Health Association
NCT00499044
Motivation and Skills Support (MASS)
Boston University Charles River Campus
NCT03404219
A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness
University Hospitals Cleveland Medical Center
NCT02085447
Prebiotic Treatment in People With Schizophrenia - Pilot Study
University of Maryland, Baltimore
NCT03617783
Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia
Massachusetts General Hospital
NCT00595504
Financial Incentives to Improve Medication Adherence
Northwell Health
NCT04191876
Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia
Yale University
NCT00793780
Neuroendocrine and Immune Response to Stress in Schizophrenia
University of Maryland, Baltimore
NCT01975584
NST-SPARK: Preliminary Study of an Augmented Reality (AR) App Delivering Recovery-Oriented Cognitive Therapy for Negative Symptoms in Schizophrenia
North Shore Therapeutics
NCT06653829
Galantamine for Cognition in People With Schizophrenia
North Suffolk Mental Health Association
NCT00320736
Effects of Pentazocine Versus Lorazepam on Manic Symptoms
Mclean Hospital
NCT00431184
Brain Stimulation and Cognitive Training - Efficacy
University of Michigan
NCT05111548
M1 Schizophrenia PET Study
Yale University
NCT05105542
Biomarkers in Schizophrenia
Nathan Kline Institute for Psychiatric Research
NCT00817336
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
Luye Pharma Group
NCT02186769
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 11 |
| Phase 3 | 4 |
| Phase 4 | 16 |
Top Sponsors
Named interventions
Most-linked intervention names on Schizoaffective Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Schizoaffective Disorder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Schizoaffective Disorder page
105 registered trials, 31 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 31 Schizoaffective Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Maryland, Baltimore sponsors the most Schizoaffective Disorder trials on record, review their full trial history before evaluating a specific study. See University of Maryland, Baltimore's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Schizoaffective Disorder condition card totals 105 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.